Use of landiolol hydrochloride, a new β-blocker, in coronary computed tomography angiography

Satoshi Isobe, Kimihide Sato, Kaichiro Sugiura, Takeo Mimura, Mikiko Kobayashi, Chizuka Meno, Makoto Kato, Hideki Ishii, Toyoaki Murohara

研究成果: ジャーナルへの寄稿学術論文査読

5 被引用数 (Scopus)

抄録

We investigated the usefulness of landiolol hydrochloride, an ultrashort-acting β1-selective agent, for coronary computed tomography angiography (CTA). Intravenous landiolol was administered to 133 patients before coronary CTA. Hemodynamic changes, adverse effects, image quality, and diagnostic accuracy for detection of coronary stenoses were evaluated. HR was significantly reduced during injection, but quickly recovered after cessation of landiolol. Neither significant changes in BP nor adverse effects were seen. The sensitivity, specificity, and positive and negative predictive values of coronary CTA for detection of significant stenoses were excellent, compared with invasive angiography. Therefore, our results show that intravenous landiolol administration gives a favorable image quality and facilitates diagnostic accuracy without causing adverse effects, indicating that landiolol is a useful premedication for coronary CTA.

本文言語英語
ページ(範囲)196-198
ページ数3
ジャーナルInternational Journal of Cardiology
139
2
DOI
出版ステータス出版済み - 04-03-2010

All Science Journal Classification (ASJC) codes

  • 循環器および心血管医学

フィンガープリント

「Use of landiolol hydrochloride, a new β-blocker, in coronary computed tomography angiography」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル